Six-Week Randomized Controlled Trial to Compare the Tolerabilities, Pharmacokinetics, and Antiviral Activities of GW433908 and Amprenavir in Human Immunodeficiency Virus Type 1-Infected Patients

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 1, 2004, Pages 116-123

  Wood, Robin ^a   Arasteh, Keikawus ^b   Stellbrink, Hans Jürgen ^c   Teofilo, Eugenio ^d   Raffi, François ^e   Pollard, Richard B ^f   Eron, Joseph ^g   Yeo, Jane ⁱ   Millard, Judith ^h   Wire, Mary Beth ^h   Naderer, Odin J ^h  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b MARTIN LUTHER KRANKENHAUS   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d Servico de Medicina 3   (Portugal)

^e NANTES UNIVERSITY HOSPITAL   (France)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF NORTH CAROLINA   (United States)

^h GLAXOSMITHKLINE   (United States)

ⁱ GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ANTIVIRUS AGENT; CD4 ANTIGEN; LAMIVUDINE; PRODRUG; PROTEINASE INHIBITOR; VIRUS RNA;

ABDOMINAL PAIN; ADULT; AGED; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CELL COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; GASEOUS SYMPTOM; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MOOD DISORDER; NAUSEA; PATIENT; PLASMA; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; SLEEP DISORDER; STEADY STATE; SYMPTOM; TABLET; TIME; URTICARIA; VOMITING;

ADOLESCENT; ADULT; AGED; ANTI-HIV AGENTS; AREA UNDER CURVE; CARBAMATES; CD4 LYMPHOCYTE COUNT; CROSS-OVER STUDIES; DIDEOXYNUCLEOSIDES; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; PHOSPHORIC ACID ESTERS; RNA, VIRAL; SULFONAMIDES;

EID: 9144240623     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.1.116-123.2004     Document Type: Article

References (13)

1. Asmuth, D. M., S. M. Hammer, and C. A. Wanke. 1994. Physiological effects of HIV infection on human intestinal epithelial cells: an in vitro model for HIV enteropathy. AIDS 8:205-211.
2. Bart, P. A., P. G. Rizzardi, S. Gallant, K. P. Golay, P. Baumann, G. Pantaleo, and C. B. Eap. 2001. Methadone blood concentrations are decreased by the administration of abacavir plus APV. Ther. Drug Monit. 23:553-555.
3. Falcoz, C., J. M. Jenkins, C. Bye, K. B. Kenney, S. Studenberg, H. Fuder, and W. T. Prince. 2002 Pharmacokinetics of GW433908, a prodrug of APV, in healthy male volunteers. J. Clin. Pharmacol. 42:887-898.
4. Haubrich, R. N., S. J. Little, J. S. Currier, D. N. Forthal, C. A. Kemper, G. N. Beall, D. Johnson, M. P. Dube, J. Y. Hwang, J. A. McCutchan, et al. 1999. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. AIDS 13:1099-1107.
5. Huang, L., S. A. Wring, J. L. Woolley, K. R. Brouwer, C. Serabjit-Singh, and J. W. Polli. 2001. Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors. Drug Metab. Dispos. 29:754-760.
6. Justesen, U. S., N. A. Klitgaard, K. Brosen, and C. Pedersen. 2003. Pharmacokinetic interaction between amprenavir and delavirdine after multiple-dose administration in healthy volunteers. Br. J. Clin. Pharmacol. 55:100-106.
7. Le Moing, V., G. Chene, M. P. Carrieri, A. Alioum, F. Brun-Vezinet, L. Piroth, J. P. Cassuto, J. P. Moatti, F. Raffi, C. Leport, et al. 2002. Predictors of virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen. AIDS 16:21-29.
8. Paterson, D. L., S. Swindells, J. Mohr, M. Brester, E. N. Vergis, C. Squier, M. M. Wagener, and N. Singh. 2000. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann. Int. Med. 133:21-30.
9. Pedneault, L., C. Brothers, G. Pagano, P. Tymkewycz, J. Yeo, J. Millard, and A. Fetter. 2000. Safety profile and tolerability of APV in the treatment of adult and pediatric patients with HIV infection. Clin. Ther. 22:1378-1394.
10. 1-acid glycoprotein on pharmacokinetics of APV, a human immunodeficiency virus protease inhibitor. Antimicrob. Agents Chemother. 45:852-856.
11. Sadler, B. M., C. Gillotin, Y. Lou, and D. S. Stein. 2001. Pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor APV after multiple oral dosing. Antimicrob. Agents Chemother. 45:30-37.
12. Tran, J. Q., C. Petersen, M. Garrett, M. Schultz-Smith, B. Hee, J. Lillibridge, and B. M. Kerr. 2001. Pharmacokinetic interaction between delavirdine and reduced dose amprenavir in HIV negative adults following multiple dosing. Clin. Infect. Dis. 33:1170.
13. Ullrich, R., W. Heise, C. Bergs, M. L'age, E. O. Riecken, and M. Zeitz. 1992. Effects of zidovudine treatment on the small intestinal mucosa in patients infected with the human immunodeficiency virus. Gastroenterology 102: 1483-1492.